Equities

Spero Therapeutics Inc

Spero Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.36
  • Today's Change0.015 / 1.12%
  • Shares traded106.34k
  • 1 Year change+9.27%
  • Beta0.6256
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Spero Therapeutics Inc grew revenues 93.95% from 53.51m to 103.78m while net income improved from a loss of 46.42m to a gain of 22.81m.
Gross margin--
Net profit margin14.74%
Operating margin13.13%
Return on assets14.03%
Return on equity25.81%
Return on investment18.79%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Spero Therapeutics Inc fell by 32.77m. Cash Flow from Financing totalled 221.00k or 0.21% of revenues. In addition the company used 33.00m for operations while cash from investing was breakeven.
Cash flow per share0.3291
Price/Cash flow per share4.11
Book value per share1.49
Tangible book value per share1.49
More ▼

Balance sheet in USDView more

Spero Therapeutics Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio2.68
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.